WASHINGTON, June 6 (Reuters) - The U.S. Supreme Court onMonday declined to hear GlaxoSmithKline Plc's bid to throw outlawsuits by union health and welfare funds that said thecompany's misrepresentation of heart-related risks of itsdiabetes medication Avandia caused them to pay too much for thedrug for insured patients.
The court left in place an October 2015 ruling by thePhiladelphia-based 3rd U.S. Circuit Court of Appeals againstLondon-based GlaxoSmithKline that allowed the classaction lawsuits to proceed. The suits were filed by three laborunion funds that provide medical coverage, including the cost ofprescription medications, to union members and their families. (Reporting by Lawrence Hurley; Editing by Will Dunham)